What is GILD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 197.40B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GILD?

P/E (TTM) is n/a and 52-week range is $114.02 to $160.51 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GILD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GILD?

The company profile lists revenue (TTM) near $30.38B, net income (TTM) near -$323.27B, EPS (TTM) near -$2.66 when available from the market-data feed. Figures are informational and may lag live markets.

Does GILD show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $4.89, yield near 3.07%, ex-dividend date Sep 15, 2026 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Gilead Sciences, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Foster City, California, US, 1.24B shares outstanding, ISIN US3755581036 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Gilead Sciences, Inc.

$GILD

Health Care · Biotechnology

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, and others. The company also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. The company has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The firm also owns an antibody-drug conjugates (ADCs) platform.

Employees

17,000

Website

www.gilead.com

IPO

1992-01-22

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US3755581036

Headquarters

Foster City, California, US

Shares outstanding

1.24B

NAICS sector

Manufacturing

Institutional ownership

92.21%

Browse other companiesFree AI scores and summaries for more stocks